SE9703375D0 - A new combination - Google Patents

A new combination

Info

Publication number
SE9703375D0
SE9703375D0 SE9703375A SE9703375A SE9703375D0 SE 9703375 D0 SE9703375 D0 SE 9703375D0 SE 9703375 A SE9703375 A SE 9703375A SE 9703375 A SE9703375 A SE 9703375A SE 9703375 D0 SE9703375 D0 SE 9703375D0
Authority
SE
Sweden
Prior art keywords
combination
pct
alkyl
enantiomer
sec
Prior art date
Application number
SE9703375A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9703375A priority Critical patent/SE9703375D0/xx
Publication of SE9703375D0 publication Critical patent/SE9703375D0/xx
Priority to ZA987817A priority patent/ZA987817B/xx
Priority to TW087114344A priority patent/TW589183B/zh
Priority to NZ503171A priority patent/NZ503171A/en
Priority to DK98944375T priority patent/DK1014985T3/da
Priority to PCT/SE1998/001601 priority patent/WO1999013877A1/en
Priority to AT98944375T priority patent/ATE240733T1/de
Priority to TR2000/00727T priority patent/TR200000727T2/xx
Priority to HU0200602A priority patent/HUP0200602A3/hu
Priority to PT98944375T priority patent/PT1014985E/pt
Priority to PL98339371A priority patent/PL339371A1/xx
Priority to DE69814882T priority patent/DE69814882T2/de
Priority to SI9830495T priority patent/SI1014985T1/xx
Priority to SK285-2000A priority patent/SK2852000A3/sk
Priority to CA002302382A priority patent/CA2302382A1/en
Priority to EEP200000141A priority patent/EE04141B1/xx
Priority to JP2000511499A priority patent/JP2001516718A/ja
Priority to KR1020007002822A priority patent/KR20010024076A/ko
Priority to US09/171,580 priority patent/US6159971A/en
Priority to CNB98811206XA priority patent/CN1195519C/zh
Priority to AU91930/98A priority patent/AU752722B2/en
Priority to BR9812088-3A priority patent/BR9812088A/pt
Priority to RU2000109563/14A priority patent/RU2214824C2/ru
Priority to IL13477698A priority patent/IL134776A0/xx
Priority to ES98944375T priority patent/ES2200370T3/es
Priority to EP98944375A priority patent/EP1014985B1/en
Priority to MYPI98004225A priority patent/MY116280A/en
Priority to ARP980104634A priority patent/AR015448A1/es
Priority to IS5406A priority patent/IS5406A/is
Priority to NO20001399A priority patent/NO20001399L/no
Priority to HK00107438A priority patent/HK1032739A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
  • Replacement Of Web Rolls (AREA)
SE9703375A 1997-09-18 1997-09-18 A new combination SE9703375D0 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
ZA987817A ZA987817B (en) 1997-09-18 1998-08-27 A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist
TW087114344A TW589183B (en) 1997-09-18 1998-08-29 A combination of a 5-HT reuptake inhibitor and a h5-HT1B antagonist or partial agonist
EP98944375A EP1014985B1 (en) 1997-09-18 1998-09-09 A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
CA002302382A CA2302382A1 (en) 1997-09-18 1998-09-09 A combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist
JP2000511499A JP2001516718A (ja) 1997-09-18 1998-09-09 ５−ＨＴ再取り込み阻害剤およびｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ
PCT/SE1998/001601 WO1999013877A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
AT98944375T ATE240733T1 (de) 1997-09-18 1998-09-09 Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten
TR2000/00727T TR200000727T2 (tr) 1997-09-18 1998-09-09 5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi.
HU0200602A HUP0200602A3 (en) 1997-09-18 1998-09-09 Pharmaceutical compositions containing a combination of a 5-ht reuptake inhibitor and a h5-ht1b antagonist or partial agonist and their use
PT98944375T PT1014985E (pt) 1997-09-18 1998-09-09 Combinacao de um inibidor de reincorporacao de 5-ht e antagonistas de h5-ht 1b ou agonista parcial
PL98339371A PL339371A1 (en) 1997-09-18 1998-09-09 Composition containing 5-ht reuptake inhibitor and antagonist or partial agonist of h5-ht 1b
DE69814882T DE69814882T2 (de) 1997-09-18 1998-09-09 Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten
SI9830495T SI1014985T1 (en) 1997-09-18 1998-09-09 A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
SK285-2000A SK2852000A3 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT1Bì (54) ANTAGONIST OR PARTIAL AGONIST
NZ503171A NZ503171A (en) 1997-09-18 1998-09-09 A combination of a 5-HT reuptake inhibitor and a h5-HT1B antagonist or partial agonist
EEP200000141A EE04141B1 (et) 1997-09-18 1998-09-09 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
DK98944375T DK1014985T3 (da) 1997-09-18 1998-09-09 Kombination af en 5-HT-genoptagelsesinhibitor og en h5-HT1B-antagonist eller delvis agonist
KR1020007002822A KR20010024076A (ko) 1997-09-18 1998-09-09 5-ＨＴ 재흡수 억제제 및 ｈ5-ＨＴ1Ｂ 길항제 또는 부분작용제의 배합물
US09/171,580 US6159971A (en) 1997-09-18 1998-09-09 Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist
CNB98811206XA CN1195519C (zh) 1997-09-18 1998-09-09 5－HT再摄取抑制剂与h5－HT1B拮抗剂或部分激动剂的组合物
AU91930/98A AU752722B2 (en) 1997-09-18 1998-09-09 A combination of a 5-HT reuptake inhibitor and a h5-HT 1B antagonist or partial agonist
BR9812088-3A BR9812088A (pt) 1997-09-18 1998-09-09 Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
RU2000109563/14A RU2214824C2 (ru) 1997-09-18 1998-09-09 Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b
IL13477698A IL134776A0 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
ES98944375T ES2200370T3 (es) 1997-09-18 1998-09-09 Una combinacion de un inhibidor de la reabsorcion de 5-ht y un antagonista o agonista parcial de h5-ht 1b.
MYPI98004225A MY116280A (en) 1997-09-18 1998-09-16 A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
ARP980104634A AR015448A1 (es) 1997-09-18 1998-09-17 COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN
IS5406A IS5406A (is) 1997-09-18 2000-03-15 Samsetning 5-HT endurupptökuhemils og h5-HT1B mótlyfs eða gerandefnis með hlutaverkun
NO20001399A NO20001399L (no) 1997-09-18 2000-03-17 Kombinasjon av en 5-HT gjenopptaksinhibitor og en h5-HT1B antagonist eller partiell agonist
HK00107438A HK1032739A1 (en) 1997-09-18 2000-11-21 A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
SE9703375D0 true SE9703375D0 (sv) 1997-09-18

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination

Country Status (30)

Country Link
US (1) US6159971A (ru)
EP (1) EP1014985B1 (ru)
JP (1) JP2001516718A (ru)
KR (1) KR20010024076A (ru)
CN (1) CN1195519C (ru)
AR (1) AR015448A1 (ru)
AT (1) ATE240733T1 (ru)
AU (1) AU752722B2 (ru)
BR (1) BR9812088A (ru)
CA (1) CA2302382A1 (ru)
DE (1) DE69814882T2 (ru)
DK (1) DK1014985T3 (ru)
EE (1) EE04141B1 (ru)
ES (1) ES2200370T3 (ru)
HK (1) HK1032739A1 (ru)
HU (1) HUP0200602A3 (ru)
IL (1) IL134776A0 (ru)
IS (1) IS5406A (ru)
MY (1) MY116280A (ru)
NO (1) NO20001399L (ru)
NZ (1) NZ503171A (ru)
PL (1) PL339371A1 (ru)
PT (1) PT1014985E (ru)
RU (1) RU2214824C2 (ru)
SE (1) SE9703375D0 (ru)
SK (1) SK2852000A3 (ru)
TR (1) TR200000727T2 (ru)
TW (1) TW589183B (ru)
WO (1) WO1999013877A1 (ru)
ZA (1) ZA987817B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
JP5080716B2 (ja) * 2001-07-20 2012-11-21 サイコジェニックス・インコーポレーテッド 注意欠陥・多動性障害の治療
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
WO2006091725A1 (en) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Treatment of anhedonia
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
EE04141B1 (et) 2003-10-15
EP1014985B1 (en) 2003-05-21
HUP0200602A3 (en) 2003-04-28
BR9812088A (pt) 2000-09-26
EE200000141A (et) 2001-02-15
NO20001399L (no) 2000-05-10
IL134776A0 (en) 2001-04-30
HUP0200602A2 (hu) 2002-07-29
CN1278729A (zh) 2001-01-03
TW589183B (en) 2004-06-01
AR015448A1 (es) 2001-05-02
ES2200370T3 (es) 2004-03-01
CA2302382A1 (en) 1999-03-25
ATE240733T1 (de) 2003-06-15
KR20010024076A (ko) 2001-03-26
US6159971A (en) 2000-12-12
ZA987817B (en) 1999-03-18
NZ503171A (en) 2002-02-01
SK2852000A3 (en) 2000-09-12
JP2001516718A (ja) 2001-10-02
NO20001399D0 (no) 2000-03-17
PT1014985E (pt) 2003-10-31
PL339371A1 (en) 2000-12-18
RU2214824C2 (ru) 2003-10-27
WO1999013877A1 (en) 1999-03-25
CN1195519C (zh) 2005-04-06
MY116280A (en) 2003-12-31
DE69814882D1 (de) 2003-06-26
TR200000727T2 (tr) 2000-09-21
HK1032739A1 (en) 2001-08-03
DE69814882T2 (de) 2004-05-19
AU752722B2 (en) 2002-09-26
AU9193098A (en) 1999-04-05
DK1014985T3 (da) 2003-09-15
IS5406A (is) 2000-03-15
EP1014985A1 (en) 2000-07-05

Similar Documents

Publication Publication Date Title
SE9703375D0 (sv) A new combination
SE9703376D0 (sv) A new combination
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
DK0794949T3 (da) Hidtil ukendte 3,5-dioxo-(2H,4H)-1,2,4-triazinderivater, fremstilling heraf og deres anvendelse som lægemidler
HUP0401307A2 (hu) 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister
SE9603283D0 (sv) New compounds
FI945581A0 (fi) Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina
PE20001234A1 (es) Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1
HUP0303270A2 (hu) Antidepresszáns hatású izoxazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69103968D1 (de) 2-(Aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre Herstellung und ihre Anwendung in der Therapeutik.
SE9804126D0 (sv) New pharmaceutical composition
SE9703374D0 (sv) A new combination
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
FI940568A0 (fi) Anti-inflammatorisina aineina toimivia oksindoli-1-(N-(alkoksikarbonyyli))karboksamideja ja -1-(N-karboksamido)-karboksamideja
AR020773A1 (es) Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto
DK0885004T3 (da) Anvendelse af 4-phenyl-3,6-dihydro-2H-pyridyl-derivater som NMDA-receptor-undertypeblokkere
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
SE9800835D0 (sv) New Compounds
SE0100344D0 (sv) New Use
HUP0001311A2 (hu) Dopamin agonista hatású 5-amino-alkoxi-1,4-dihidro-kinoxalin-2,3-dion-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
AR009445A1 (es) Compuestos n-(piridinilamino)isoindolinas y compuestos relacionados, composiciones farmaceuticas, usos en la fabricacion de medicamentos para eltratamiento de la disfuncion de la memoria y la depresion, procedimiento de preparacion de dichos compuestos y compuestos intermediarios
HUP0202237A2 (hu) Amin, módosított pszeudomicin vegyületek, azokat tartalmazó gyógyászati készítmény és alkalmazásuk